SCYX
SCYNEXIS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 4 ▲ Scynexis reported a significant year-over-year revenue increase to $…
- Mar 31 ▲ Scynexis (SCYX) announced the acquisition of PXL-770 (now SCY-770),…
- Apr 1 ▲ 1 insider buy $0.00
- May 11 ▼ SCYNEXIS reported Q1 2026 results with a GAAP net loss of $0.42 per…
- Jul 31 Trading halt: Halt Resumed: SCYX, trading resumed after LUDP (Volatility…
- Sep 28 ▲ SCYNEXIS announced a BARDA contract worth up to ~$214M (if all optio…
- Sep 28 Contract: SCYNEXIS Awarded BARDA Contract Providing Up to $214 Milli…
- Sep 30 ▼ Short interest jumps 29.3% to 594.3K
- Oct 6 FDA: SCYNEXIS Announces Phase 1 Study Results for SCY-770, a No…
- Oct 15 ▲ Short interest falls 29.2% to 420.5K
- Oct 22 FDA: SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a…
- Oct 22 ▲ Scynexis announced positive Phase 1 topline results for IV SCY-247,…
Signal stack
Where each data set points today.
- InsidersMIXED
No open-market sales.
- InstitutionsMIXED
Q3 2026: 4 added (0 new), 4 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.720 → −$0.627 over 90 days. 1 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +7.1% to 450.2K shares. 5.5 days to cover, ≈4.5% of shares.
- TrendDOWNTREND
30% below its 50-day average. New closing low $2.91 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | ADD | $2.1M |
| GEODE CAPITAL MANAGEMENT, LLC | ADD | $595.7K |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $256.0K |
| STATE STREET CORP | ADD | $118.0K |
| UBS Group AG | NEAR_EXIT | $13.4K |
| MORGAN STANLEY | TRIM | $10.5K |
| NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | DOUBLED | $4.3K |
| BARCLAYS PLC | NEAR_EXIT | $10.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Aug 2026Price is below the lowest target. Median implies +1034%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Aug 13, 2026 | Guggenheim MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Burke Steven Keith Director Sep 18, 2026 | AWARD | 5,750 sh |
Burke Steven Keith Director Sep 18, 2026 | AWARD | 5,750 sh |
Subramanian Sanjay Chief Financial Officer Sep 9, 2026 | AWARD | 100,000 sh |
HANHAM ANN Director Jun 26, 2026 | AWARD | 2,875 sh |
HANHAM ANN Director Jun 26, 2026 | AWARD | 2,875 sh |
HASTINGS DAVID C Director Jun 26, 2026 | AWARD | 2,875 sh |
HASTINGS DAVID C Director Jun 26, 2026 | AWARD | 2,875 sh |
ANIDO ARMANDO Director Jun 26, 2026 | AWARD | 2,875 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.63 | -$0.82–-$0.43 | +7.2% | $237.5K |
| Next Q | -$0.58 | -$0.69–-$0.38 | No data | $694.5K |
| Current FY | -$3.13 | -$3.48–-$2.85 | -7.6% | $393.3K |
| Next FY | -$1.95 | -$2.90–-$0.37 | +15.6% | $9.7M |
Short side
FINRA· Oct 30, 2026| Jul 31, 2026 | Volatility Pause | Resumed |
| Jul 31, 2026 | Volatility Pause | Resumed |
SecBot reports
9 filings · 5 press releases · 0 bullish · 1 bearish · 8 neutral- NEUTRAL SC 13G/ANov 16, 2026
Great Point Partners LLC filed an amended Schedule 13G for SCYNEXIS Inc, reporting beneficial ownership of 4,076,068 shares (9.99% of common stock) as of September 30, 2026. The filing is an amendment updating the reporting date and share count; the stake appears unchanged from the prior filing…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL S-3Nov 5, 2026
SCYNEXIS filed a new S-3 shelf registration to replace its expiring 2023 S-3, carrying forward the…
This is a routine shelf replacement with no immediate capital raise. Monitor for future prospectus supplements that would signal an actual offering. The I.B.6 limitation restricts primary offerings…
- NEUTRAL PRESS-RELEASENov 5, 2026
Scynexis reported Q3 2026 net loss of $8.5M ($0.71 per share) vs consensus EPS of -$0.72, a slight…
Watch for initiation of SCY-770 Phase 2 trial in Q4 2026 and any interim data in Q4 2027. Also monitor BARDA option exercises for SCY-247 funding. The cash runway into 2029 reduces near-term…
- BULLISH PRESS RELEASEOct 22, 2026
Scynexis announced positive Phase 1 topline results for IV SCY-247, showing good tolerability and…
Phase 1 success de-risks SCY-247's IV formulation; watch for FDA alignment on Phase 2 design and milestone triggers under the BARDA contract. The BARDA award significantly reduces dilution risk for…
All SCYX filing & press-release reports (14)
- SC 13G/A reportNov 16, 2026
- S-3 reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- PRESS-RELEASE reportOct 22, 2026
- PRESS-RELEASE reportOct 6, 2026
- PRESS-RELEASE reportSep 28, 2026
- 8-K reportSep 22, 2026
- 8-K reportSep 10, 2026
- 8-K reportJun 26, 2026
- 8-K reportMay 22, 2026
- PRESS-RELEASE reportMay 11, 2026
- 8-K reportApr 20, 2026
- PRESS-RELEASE reportMar 31, 2026
- PRESS-RELEASE reportMar 4, 2026